3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
48
Lung Neoplasms
23
Carcinoma, Hepatocellular
23
Small Cell Lung Carcinoma
16
Urinary Bladder Neoplasms
11
Cholangiocarcinoma
11
Breast Neoplasms
10
Biliary Tract Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Liver Neoplasms
8
Pancreatic Neoplasms
6
Carcinoma
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Interventions
Bevacizumab
4
palbociclib
2
ribociclib
1
repotrectinib
1
olaparib
1
encorafenib
1
durvalumab
1
atezolizumab
1
Tretinoin
1
Paclitaxel
1
Oviposition
1
Leucovorin
1
Irinotecan
1
Injections
1
Immunotherapy
1
Imatinib Mesylate
1
Fulvestrant
1
Fluorouracil
1
Drug Therapy
1
Drainage
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Digestive System Neoplasms
×
durvalumab
×
90 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled